Angiotensin-converting enzyme
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Angiotensin-converting enzyme as ChEMBL target CHEMBL4074, mapped to UniProt P12822. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Angiotensin-converting enzyme matters
Angiotensin-converting enzyme is reviewed as Angiotensin-converting enzyme (UniProt P12822); the current evidence base includes 11 approved drugs, 1744 compounds, and 137 assays, with lead potency reaching pChEMBL 10.7.
Angiotensin-converting enzyme Sequence length is 1310 aa.
Review this target as Angiotensin-converting enzyme, mapped to UniProt P12822. Sequence length is 1310 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 11 approved drugs, 1744 compounds, and 137 assays for this target. The dominant activity type is IC50. CHEMBL112589 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL112589 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Angiotensin-converting enzyme matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P12822, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL112589
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL113612
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL324898
|
10.6 | IC50 | — |
|
|
No preferred name
CHEMBL323879
|
10.6 | IC50 | — |
|
|
No preferred name
CHEMBL112922
|
10.1 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
BENAZEPRIL
CHEMBL838
|
1991 |
|
|
QUINAPRIL
CHEMBL1592
|
1991 |
|
|
RAMIPRIL
CHEMBL1168
|
1991 |
|
|
ENALAPRILAT ANHYDROUS
CHEMBL577
|
1988 |
|
|
LISINOPRIL ANHYDROUS
CHEMBL1237
|
1987 |
|
|
ENALAPRIL
CHEMBL578
|
1985 |
|
|
CAPTOPRIL
CHEMBL1560
|
1981 |